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Available online 24 May 2018Objective: Antipsychotic blood levels (ABLs) may help identify patients at risk for treatment failure. Reference
ranges (RR) for plasma concentrations of ABLs that account for between-patient variability were developed for
risperidone and olanzapine based on population pharmacokineticmodels. The Clinical Antipsychotic Trials of In-
tervention Effectiveness (CATIE) collected clinical outcomes andABLs, allowing testing of the relationship of ABLs
with outcomes.
Methods: ABLs from 694 patients whowere randomized to olanzapine or risperidone were compared to the 80%
RRs and were assessed as below or within/above the RR. Treatment failure was deﬁned per any of these criteria:
(1) emergency room visit for psychiatric reasons, (2) hospitalization for psychiatric reasons, (3) adverse event of
completed suicide, suicidal ideation, or suicide attempt, (4) assaultive behavior, (5) arrested or jailed, (6) 2-point
increase from baseline in Clinical Global Impression-Severity score, (7) 25% increase in Positive and Negative
Syndrome Scale total score. Patients assessed with treatment failurewithin 100 days of drug concentrationmea-
surement were analyzed.
Results: Treatment failure occurred in 126 of 323 patients. The proportion of patients with ABLs below RR was
18.3% (59/323) compared to 10% expected in a fully adherent population. Among the 59 with ABLs below RR,
50.8% had treatment failure (compared to 36.4% for the 264with ABLswithin/above RR). The difference between
groups was signiﬁcant (odds ratio = 1.810; 95% CI = 1.025, 3.197; p= 0.0408).
Conclusions:Analysis of CATIE data showed that ABLswithin the context of RRsmay identify patients with higher
risk of relapse.. This is©2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Schizophrenia, a severe psychiatric disorder, affects N21million peo-
pleworldwide (World Health Organization, 2017). The disorder is char-
acterized by cognitive impairment as well as positive and negative
symptoms, usually requiring lifelong treatment.
The majority of patients with schizophrenia will be at least partially
non-adherent during their treatment (Byerly et al., 2007; Marder,
2013). Non-adherence, a primary factor in disease relapse, also incurs
high health care and societal costs (Acosta et al., 2012; Novick et al.,
2010). Even partial non-adherence increases risk of relapse (Weiden
et al., 2004).
A retrospective review using a strict set of study inclusion criteria
found mean nonadherence rates between 41.2% and 49.5% (Lacroan open access article underet al., 2002). Valenstein et al. assessed approximately 34,000 Veterans
Affairs patients with schizophrenia for 4 consecutive years. The cross-
sectional prevalence of poor adherence was stable over time, with
about 37% being poorly adherent each year, and 61% of patients had
poor adherence at some point over 4 years (Valenstein et al., 2006).
Methods to assess adherence such as clinician ratings, pill counts, pa-
tient reports, prescription renewal, urine/blood levels, and electronic
monitoring have limited ability to detect antipsychotic non-adherence
(Acosta et al., 2012; Byerly et al., 2005; Kane et al., 2013; Velligan
et al., 2009).
Antipsychotic blood levels (ABLs) can be used as an approach to im-
prove the reliability of adherence assessment, with the understanding
that they may only reﬂect recent adherence behavior, as well as rapid
elimination of the drug and treatment resistance (Hiemke et al., 2011;
Horvitz-Lennon et al., 2017; Howes et al., 2017). A recently developed
method of “reference ranges” (RRs) for risperidone and olanzapine
was used in this study to better interpret plasma concentrations ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Reference ranges for once-daily dosing of risperidone and olanzapine.
Average concentrationa (ng/mL)
Time Since Last
Dose:
0 to 4 h 4 to 9 h 9 to 14 h 14 to 20 h 20 to 24 h
Percentile: ≤10 ≥90 ≤10 ≥90 ≤10 ≥90 ≤10 ≥90 ≤10 ≥90
Risperidone
1 mg 5.33 22.1 5.57 21.7 4.50 18.2 3.55 15.3 2.86 13.1
2 mg 10.7 44.2 11.1 43.5 9.01 36.4 7.10 30.6 5.72 26.2
3 mg 16.0 66.3 16.7 65.2 13.5 54.7 10.6 45.8 8.58 39.3
4 mg 21.3 88.4 22.3 87.0 18.0 72.9 14.2 61.1 11.4 52.5
5 mg 25.6 104 27.4 106 22.5 89.9 17.7 75.9 14.3 65.3
6 mg 32.0 133 33.4 130 27.0 109 21.3 91.7 17.2 78.7
8 mg 42.6 177 44.6 174 36.0 146 28.4 122 22.9 105
Olanzapine
2.5 mg 3.75 11.2 4.05 11.9 3.50 10.7 2.78 9.86 2.16 9.25
5 mg 7.50 22.4 8.10 23.7 7.00 21.4 5.56 19.7 4.32 18.5
7.5 mg 11.2 33.6 12.2 35.6 10.5 32.1 8.35 29.6 6.49 27.7
10 mg 15.0 44.7 16.2 47.4 14.0 42.8 11.1 39.4 8.65 37.0
15 mg 22.5 67.1 24.3 71.1 21.0 64.3 16.7 59.2 13.0 55.5
20 mg 30.0 89.5 32.4 94.9 28.0 85.7 22.3 78.9 17.3 74.0
h = hours.
a Concentrations represent active moiety for risperidone and parent molecule for
olanzapine.
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ulation pharmacokinetic models of fully adherent patients, and account
for between- and within-patient variability for a given dose and time
after dose. Use of RRs for assessment of ABLs may provide a reliable in-
dication of treatment adherence (Green et al., 2017; Korell et al., 2017).
The Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) study, designed to compare the effectiveness of atypical and
conventional antipsychotic drugs, collected clinical outcomes and ABLs
(Lieberman et al., 2005). The purpose of this study was to assess the re-
lationship between the incidence of treatment failure and ABLs within
the context of RRs in patients with schizophrenia using data from the
CATIE trial.
2. Methods
Methods for the conduct of the CATIE trial have been previously de-
scribed (Lieberman et al., 2005). Brieﬂy, a total of 1493 patients with
schizophrenia were randomized to perphenazine, olanzapine,
quetiapine, risperidone or ziprasidone for up to 18months of treatment.
The CATIE protocol included obtaining random blood samples to mea-
sure antipsychotic levels. The limited access data sets distributed from
the CATIE trial provided ABLs from 694 patients who were randomized
to either olanzapine or risperidone.
Patients were identiﬁed as treatment failures based on presence of
any of the following criteria: (1) emergency room visit for psychiatric
reasons, (2) hospitalization for psychiatric reason, (3) adverse event of
completed suicide, suicidal ideation, or suicide attempt, (4) assaultive
behavior, (5) being arrested or jailed, (6) 2-point increase frombaseline
in the Clinical Global Impression-Severity (CGI-S) score, (7) 25% in-
crease in the Positive and Negative Syndrome Scale (PANSS) total
score (Table 1). The clinical outcomes in CATIE were reviewed and
these criteria were selected as most relevant for poor clinical outcome
based on signiﬁcant negative behavior or meaningful change in a rating
scale, i.e., a 25% increase in PANSS (Csernansky et al., 2002).
2.1. Development of reference ranges
Eighty percent populationRRswere developed and evaluated for ris-
peridone and olanzapine, based on oral formulation data (Korell et al.,
2018; Korell et al., 2017). Population pharmacokinetic (pop-PK)models
were developed using plasma concentrations data from patients with
observed medication intake during phase 2 and 3 registration trials,
and were internally validated by the sponsors of each antipsychotic
agent (risperidone, Janssen Research & Development, Raritan, NJ;
olanzapine, Eli Lilly and Company, Indianapolis, IN).
A database of patients and their demographic characteristics was
constructed from patients who participated in 25 clinical trials during
development of Janssen's antipsychotics. The characteristics and covar-
iates from this databasewere used to simulate expected concentrations,
assuming perfect compliance with the prescribed treatment regimen
described above. The simulated concentrations were sorted into 80%
population RRs for the test analytes. Plasma concentrations for 80% of
the fully adherent patient population are represented by the range be-
tween the lower 10% and upper 90% boundaries (Table 2). In otherTable 1
Treatment failure criteria.
1. Use of emergency room for psychiatric reasons
2. Hospitalization for psychiatric reasons
3. Adverse event (completed suicide, depression suicidal, suicidal ideation,
suicide attempt)
4. Assaultive behavior such as violent/non-violent crime, violence
5. Arrested, or spent nights in jail
6. 2-point increase from baseline in Clinical Global Impression-Severity score
7. 25% increase in Positive and Negative Syndrome Scale total scorewords, even in fully adherent subjects, 10% of subjects will be below
and above the RR.
The RRs were time-binned to account for the change in plasma con-
centrations as a function of time after a dose. The 80% RRs were gener-
ated, taking into account the terms representing variability between
patients and within patients (i.e., residual variability) from the pop-PK
models. The 80% RRs were evaluated externally, using new sets of stud-
ies, which were different from the studies used to build the pop-PK
models. For both risperidone and olanzapine, the RRs are available for
the most commonly used marketed doses, and for both once-daily and
twice-daily regimens (Korell et al., 2017; Korell et al., 2018).
2.2. Assessment
Drug concentrations were measured every three months in the
CATIE study. Although the visits were 90 days apart, we added in 10 ad-
ditional days in selecting the patients. Only those patients who had an
assessment of treatment failure within 100 days from the visit where
the drug concentrations were measured were included in the evalua-
tion. To make a prudent association between the drug concentration
levels and the treatment failure status, patients who skipped the visit
after the blood draw, those who discontinued from the study after
blood draw, or those who did not adhere to the study visit schedule
had to be excluded from the analysis as inclusion of the data from
these patients would have made our analysis less sensitive to drug con-
centration levels. Treatment failure status within the 100-day window
wasmapped to the drug concentration ﬂag at the previous visit. For pa-
tients who were treatment failures at multiple visits, their ﬁrst occur-
rence of treatment failure and its corresponding drug concentration
ﬂag at the previous visit was used for the analysis.
Distribution of ABL categories in the treatment failure group was
compared to the distribution in the non-treatment failure group. Odds
ratio (OR) (95% CI) of incidence rate of treatment failure in the below
range group vs within/above range group was estimated.
Patients who were randomized to olanzapine or risperidone during
phases 1/1B/2 and had drug concentration data within the dosing inter-
vals for which RRs were available, were compared to the 80% RRs and
were assessed as below or within/above the RR. Patients were counted
separately for each treatment (i.e., olanzapine or risperidone) in deter-
mining treatment failure and in assessing whether they were below or
within/above the RR. However, they were counted once in the assess-
ment of demographic summaries.
Table 4
Demographics and baseline characteristics (N= 316).
Age, years, n (%)
18–25 38 (12.0)
26–50 220 (69.6)
51–64 57 (18.0)
N64 1 (0.3)
Mean (SD) 40.9 (11)
Median (range) 43 (18; 67)
Race, n (%)
American Indian/Alaska Native 3 (0.9)
Asian 11 (3.5)
Black or African American 98 (31.0)
Hawaiian or Paciﬁc Islander 1 (0.3)
More than one race 2 (0.6)
White 201 (63.6)
Sex, n (%)
Male 227 (71.8)
Female 89 (28.2)
Treatment, n (%)a
Risperidone 139 (44.0)
Olanzapine 184 (58.2)
n = number, SD = standard deviation.
a 7 patients were on risperidone as well as olanzapine in two different phases.
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on the individual criteria that were considered in the deﬁnition
(Table 3).
3. Results
Out of the 694 patients who had ABLs, a total of 316 patients were
included in the analysis of treatment failure (Table 4). There were 7 pa-
tients who were on risperidone as well as olanzapine. When we
assessed treatment failure rates in relation to drug levels, we counted
these patients twice – once for olanzapine and once for risperidone.
These patients were categorized as below or within/above reference
range separately for each medication. The number of patients receiving
risperidone was 139 (44.0%), and the number of patients receiving
olanzapine was 184 (58.2%). Therefore, the total for the All category
was 323. The number of patients used in the analysis of treatment fail-
ure in each group varied depending on the deﬁnition. Fig. 1 shows the
incidence of treatment failure based on the drug concentration being
below the RR or within/above the RR, in speciﬁed categories of treat-
ment failure criteria. The majority of categories show a lower percent-
age of treatment failure with drug concentrations within/above the RR
as compared to below the RR.
In the All Criteria category, treatment failure occurred in 39.0% (126/
323) of the patients. The proportion of patients who had drug concen-
tration below the RR was 18.3% (59/323). Out of the 59 patients with
ABLs below range, 30 (50.8%) had treatment failure compared to 96
(36.4%) out of 264 patients with levels within/above range who had
treatment failure. The difference between the two drug concentration
groups was signiﬁcant (OR [95% CI]: 1.810 [1.025, 3.197]; p= 0.0408).
In the deﬁnition that excluded assaultive behavior or jail (Clinical),
treatment failure occurred in 32.7% (106/324) of the patients. The pro-
portion of treatment failures in the below range group was 44.1% (26/
59) compared to 30.2% (80/265) in the within/above range group (OR
[95% CI]: 1.822 [1.023, 3.245]; p = 0.0416). In the deﬁnition of treat-
ment failure which did not include the PANSS (No PANSS) treatment
failure occurred in 26.7% (93/348) of the patients. The proportion of
treatment failures in the below range group was 39.7% (23/58) com-
pared to 24.1% (70/290) in the within/above range group (OR [95%
CI]: 2.065 [1.144, 3.729]; p= 0.0161). Criteria were met for treatment
failure due to a 2-point increase from baseline in CGI-S scores (CGI-S)
in 6.2% (23/373) of the patients. The proportion of treatment failure in
the below range group was 14.8% (9/61) compared to 4.5% (14/312)
in the within/above range group (OR [95% CI]: 3.684 [1.516, 8.950];
p=0.0040). Criteria for treatment failure weremet due to hospitaliza-
tion or emergency room visit for psychiatric reasons (Hosp/ER) in 13.2%
(46/348) of the patients. The proportion of treatment failures in the
below range group was 17.9% (10/56) compared to 12.3% (36/292) inTable 3
Speciﬁed groups of treatment failure criteria.
Criteria All
n
=
323
Clinical
n=
324
Legal
n=
384
Scales
n=
356
PANSS
n=
354
CGI-S
n=
373
Use of emergency room for psychiatric
reasons
x x
Hospitalization for psychiatric reasons x x
Adverse event (completed suicide,
depression suicidal, suicidal ideation,
suicide attempt)
x x
Assaultive behavior (violent/non-violent
crime, violence)
x x
Arrested, or spent nights in jail x x
2-point increase from baseline in CGI-S
score
x x x x
25% increase in PANSS total score x x x x
AE = adverse event, CGI-S = Clinical Global Impression-Severity, ER = emergency room, Hosthe within/above range group (OR [95% CI]: 1.546 [0.717, 3.331]; p =
0.2661). Treatment failure rate by drug concentration category below
the RR vs within/above the RR was signiﬁcant (p b 0.05) for All, Clinical,
Scales, CGI-S, combined category of Legal/CGI-S, No PANSS, and com-
bined category of No PANSS/No Hosp categories (Fig. 2).
4. Discussion
Analysis of the CATIE data showed signiﬁcantly higher relapse rates
were observed in patients with ABLs below RRs compared to ABLs
within/above RRs (OR [95% CI]: 1.810 [1.025, 3.197]; p= 0.0408).
Criteria grouped into categories of treatment failure frequency and
rate by drug concentration were assessed within categories. The pro-
portion of treatment failures with ABLs below range was higher than
the proportion of ABLs within/above range in most categories, although
the difference between rate of treatment failures and ranges were sig-
niﬁcant in only about half of the categories.
Although deﬁnitive conclusions cannot bemade regarding the inﬂu-
ence of each category on the proportion of treatment failures for ABLs
below range compared to ABLswithin/above range, categories with sig-
niﬁcantly more treatment failures with ABLs below range than with
ABLs within/above range included All criteria (p = 0.0408), Clinical
(all criteria except assaultive behavior or jail) (p= 0.0416), and Scales
(a 2-point increase from baseline in CGI-S score, and a 25% increase in
PANSS total score) (p = 0.0251). The PANSS category had a higherLegal/CGI-S
n= 382
AE/Hosp/ER
n= 348
AE/ER
=373
Hosp/ER
n = 348
No
Hosp
n
=
357
No
PANSS
n =
348
No
PANSS/No
Hosp n=
380
AE
n
=
373
x x x x x x
x x x
x x x x x x
x x x x
x x x x
x x x x
x
p = hospitalization, PANSS = Positive and Negative Syndrome Scale.
Fig. 1. Frequency distribution of treatment failure status by drug concentration category. Abbreviations: AE = adverse event, B = below reference range, CGI-S = Clinical Global
Impression-Severity, conc = concentration, ER = emergency room, hosp = hospitalization, PANSS = Positive and Negative Syndrome Scale, W/A = within/above reference range.
Fig. 2. Treatment failure rate by drug concentration category – below reference range vs within/above reference range (odds ratio [95% CI]). Abbreviations: AE= adverse event, CGI-S =
Clinical Global Impression-Severity, ER = emergency room, hosp = hospitalization, PANSS = Positive and Negative Syndrome Scale.
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category (6.2% [23/373]), however, the treatment failure rate in the
CGI-S category was signiﬁcantly higher in ABLs below range than
ABLs within/above range (p = 0.0040) than in the PANSS category
(p = 0.1404). Some of the deﬁnitions of treatment failure appeared
to bemore sensitive to the drug levels with regards to treatment failure
as seen in the categories of No PANSS, Legal/CGI (combined category),
CGI-S and Scales compared to the others.
Using the RRs, ABLs can be checked for consistency with what is ex-
pected for a given formulation, dose, and time after dose. Perfect adher-
ence was assumed when deﬁning the RRs. Due to naturally occurring
variation, 10% of patients are expected below-RR ABLs despite perfect
adherence. It is therefore not surprising to ﬁnd that N10% (in this case
18%) of patients from the CATIE evaluation dataset had below-RR
ABLs, since the occurrence of partial- or non-adherence is expected
even within controlled trials (especially when oral medications are
used). Considering that this was a well-controlled trial with pill counts,
it would be expected that in a clinical population an even higher per-
centage would be below the RR but this would need to be tested in a
more naturalistic setting. It should be noted that the system can bemis-
led by taking the medication shortly before the measurement takes
place, and levels could then be in range even if patients were non-
adherent the previous days. Therefore, 10% is not an absolute cut-off.
The ﬁndings of the present analysis of CATIE data suggest ABLs may
function as a potential risk factor for treatment failure but would be in-
sufﬁciently sensitive or speciﬁc to reliably predict treatment failure on
their own. Consequently, ABLs need to be combinedwith clinical evalu-
ation of the patient.When a patient experiences a treatment failure, it is
often difﬁcult to determine if the cause is lack of adherence, lack of efﬁ-
cacy of themedication, or a drug interaction that reduces the efﬁcacy of
the antipsychotic. In cases with low ABLs, treatment failure is often a re-
sult of sustained concentrations below the RR, which can result from
lack of adherence or unaccounted drug-drug interactions. Smoking
and CYP2D6 metabolizer status were included as covariates in the
POP-PK models used to generate the 80% reference ranges. Therefore,
the reference ranges also reﬂect variability due to these covariates. Nev-
ertheless, smoking and rapid metabolizer status will increase the prob-
ability for detecting concentrations below the 80% RR for olanzapine
and risperidone, respectively.
Our study reports the use of RRs in a retrospective analysis of ABLs
and incidence of treatment failure from the CATIE trial. The use of
ABLswithRRs and treatment failurewould need to be characterized fur-
ther in clinical trials, as well as used with other antipsychotics. Plasma
concentration RRs for oral aripiprazole, paliperidone, and quetiapine
have also been developed (Korell et al., 2018; Korell et al., 2017).
ABLs within the context of RRs can potentially identify patients with
higher risk of treatment failure. With the use of ABLs in relation to RRs,
the clinician may gain conﬁdence in better assessing treatment adher-
ence in some patients and potentially intervene prior to a full treatment
failure. These results could be used to direct appropriate treatment.
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